AVM Biotechnology

Avm Biotechnology

Biotechnology, 1749 Dexter Ave N, Seattle, Washington, 98109, United States, 11-50 Employees

avmbiotech.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 20********

Who is AVM BIOTECHNOLOGY

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical tr...

Read More

map
  • 1749 Dexter Ave N, Seattle, Washington, 98109, United States Headquarters: 1749 Dexter Ave N, Seattle, Washington, 98109, United States
  • 2008 Date Founded: 2008
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AVM BIOTECHNOLOGY

AVM Biotechnology Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AVM Biotechnology

Answer: AVM Biotechnology's headquarters are located at 1749 Dexter Ave N, Seattle, Washington, 98109, United States

Answer: AVM Biotechnology's phone number is 20********

Answer: AVM Biotechnology's official website is https://avmbiotech.com

Answer: AVM Biotechnology's revenue is $5 Million to $10 Million

Answer: AVM Biotechnology's SIC: 8731

Answer: AVM Biotechnology's NAICS: 541714

Answer: AVM Biotechnology has 11-50 employees

Answer: AVM Biotechnology is in Biotechnology

Answer: AVM Biotechnology contact info: Phone number: 20******** Website: https://avmbiotech.com

Answer: AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta+ Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access